ENDRA LIFE SCIENCES INC (NDRA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
$4.75-2.66%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-29
Research Workspace
Put NDRA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Reduce cash burn to less than -$1.12M in operating cash flow: Comparison needs review.
View ThesisManagement screens weak on capital allocation, earnings delivery.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 51% in its worst 12-month stretch.
View RiskNDRA’s merger-led growth case depends on pursuing acquisitions despite unsteady management and weak recent performance. The latest quarter beat, but the desk shows no revenue-growth history. Reported GAAP earnings were $0.16 per share versus a consensus loss of $0.84. No valuation multiples are available, so the price’s expectations cannot be defined. Our model puts the next-quarter miss probability near 62%. The thesis pillar on reducing operating cash burn needs review. Peer multiples cannot provide a valuation read because that data is omitted. This read is provisional, and the thesis is on watch.
Trailing returns as of 2026-10-30. NDRA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering NDRA (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NDRA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NDRA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put NDRA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Pursue merger and acquisition activities
Merger filing aligns with growth strategy and enhances market position.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Pursue merger and acquisition activities
Amendment supports growth through M&A activities.
